Beyond aromatherapy: can essential oil loaded nanocarriers revolutionize cancer treatment?

Obaydah Abd Alkader Alabrahim, Jude Majed Lababidi, Wolfgang Fritzsche, Hassan Mohamed El-Said Azzazy
Author Information
  1. Obaydah Abd Alkader Alabrahim: Department of Chemistry, School of Sciences & Engineering, The American University in Cairo AUC Avenue, SSE # 1184, P.O. Box 74 New Cairo 11835 Egypt Obaydah.alabrahim@aucegypt.edu jlababidi@aucegypt.edu hazzazy@aucegypt.edu. ORCID
  2. Jude Majed Lababidi: Department of Chemistry, School of Sciences & Engineering, The American University in Cairo AUC Avenue, SSE # 1184, P.O. Box 74 New Cairo 11835 Egypt Obaydah.alabrahim@aucegypt.edu jlababidi@aucegypt.edu hazzazy@aucegypt.edu.
  3. Wolfgang Fritzsche: Department of Nanobiophotonics, Leibniz Institute of Photonic Technology Albert Einstein Str. 9 Jena 07745 Germany.
  4. Hassan Mohamed El-Said Azzazy: Department of Chemistry, School of Sciences & Engineering, The American University in Cairo AUC Avenue, SSE # 1184, P.O. Box 74 New Cairo 11835 Egypt Obaydah.alabrahim@aucegypt.edu jlababidi@aucegypt.edu hazzazy@aucegypt.edu. ORCID

Abstract

Cancer, a complex global health burden, necessitates the development of innovative therapeutic strategies. While chemotherapy remains the primary treatment approach, its severe side effects and chemoresistance drive the search for novel alternatives. Essential oils (EOs), consisting of diverse bioactive phytochemicals, offer promise as anticancer agents. However, their limitations, such as instability, limited bioavailability, and non-specific targeting, hinder their therapeutic potential. These challenges were circumvented by utilizing nanoparticles and nanosystems as efficient delivery platforms for EOs. This review highlights the accumulating evidence based on loading EOs into several nanocarriers, including polymeric nanoparticles, nanoemulsions, nanofibers, lipid-based nanocapsules and nanostructures, niosomes, and liposomes, as effective anticancer regimens. It covers extraction and chemical composition of EOs, their mechanisms of action, and targeting strategies to various tumors. Additionally, it delves into the diverse landscape of nanocarriers, including their advantages and considerations for cancer targeting and EO encapsulation. The effectiveness of EO-loaded nanocarriers in cancer targeting and treatment is examined, highlighting enhanced cellular uptake, controlled drug release, and improved therapeutic efficacy. Finally, the review addresses existing challenges and future perspectives, emphasizing the potential for clinical translation and personalized medicine approaches.

References

  1. J Chromatogr A. 2012 Aug 10;1250:34-48 [PMID: 22595519]
  2. Pharmaceutics. 2022 Oct 15;14(10): [PMID: 36297630]
  3. J Control Release. 2021 Jul 10;335:457-464 [PMID: 34048841]
  4. Nat Rev Dis Primers. 2019 Sep 23;5(1):66 [PMID: 31548545]
  5. Molecules. 2017 Jul 14;22(7): [PMID: 28708073]
  6. Molecules. 2020 Oct 16;25(20): [PMID: 33081286]
  7. Int J Nanomedicine. 2020 Feb 05;15:795-807 [PMID: 32103937]
  8. Adv Mater. 2019 Jan;31(3):e1802244 [PMID: 30156333]
  9. Soft Matter. 2016 Mar 21;12(11):2826-41 [PMID: 26924445]
  10. Nano Lett. 2017 May 10;17(5):2879-2886 [PMID: 28287740]
  11. ACS Appl Mater Interfaces. 2020 Dec 16;12(50):56499-56508 [PMID: 33275401]
  12. Nano Converg. 2021 Nov 2;8(1):34 [PMID: 34727233]
  13. Food Chem Toxicol. 2010 Jul;48(7):1801-5 [PMID: 20385197]
  14. Nanoscale Res Lett. 2021 Dec 5;16(1):173 [PMID: 34866166]
  15. J Microencapsul. 2015;32(7):699-704 [PMID: 26004370]
  16. Biochem Biophys Res Commun. 2004 Mar 12;315(3):589-94 [PMID: 14975741]
  17. BMC Complement Med Ther. 2023 Nov 28;23(1):428 [PMID: 38017466]
  18. Clin Med Insights Oncol. 2016 Oct 09;10(Suppl 1):57-66 [PMID: 27773999]
  19. Nat Rev Clin Oncol. 2022 Nov;19(11):681-697 [PMID: 36221000]
  20. J Microencapsul. 2011;28(5):406-16 [PMID: 21736525]
  21. Cancer Lett. 2006 Apr 8;235(1):114-20 [PMID: 15979235]
  22. Phytother Res. 2007 Apr;21(4):308-23 [PMID: 17199238]
  23. Fitoterapia. 2003 Apr;74(3):317-9 [PMID: 12727504]
  24. Food Chem. 2008 Jun 1;108(3):986-95 [PMID: 26065762]
  25. Res Commun Mol Pathol Pharmacol. 2001;110(3-4):239-51 [PMID: 12760491]
  26. Eur J Med Res. 1998 Nov 17;3(11):508-10 [PMID: 9810029]
  27. Evid Based Complement Alternat Med. 2018 Mar 25;2018:3149362 [PMID: 29765461]
  28. Molecules. 2022 Jun 06;27(11): [PMID: 35684577]
  29. ACS Omega. 2023 Jun 13;8(25):22774-22782 [PMID: 37396262]
  30. Nanoscale Adv. 2023 Dec 22;6(3):910-924 [PMID: 38298595]
  31. PLoS One. 2022 Jan 24;17(1):e0262335 [PMID: 35073347]
  32. Chem Rev. 2019 Apr 24;119(8):5298-5415 [PMID: 30916938]
  33. Front Med (Lausanne). 2022 Sep 12;9:995882 [PMID: 36172536]
  34. J Food Biochem. 2019 Aug;43(8):e12956 [PMID: 31368576]
  35. Sci Rep. 2020 Feb 18;10(1):2812 [PMID: 32071359]
  36. Evid Based Complement Alternat Med. 2015;2015:397821 [PMID: 25722735]
  37. J Agric Food Chem. 2013 Nov 20;61(46):10835-47 [PMID: 24156356]
  38. Cancers (Basel). 2019 Mar 08;11(3): [PMID: 30857233]
  39. Semin Cancer Biol. 2021 Feb;69:52-68 [PMID: 32014609]
  40. Molecules. 2022 Mar 15;27(6): [PMID: 35335262]
  41. Pharmaceutics. 2022 May 13;14(5): [PMID: 35631634]
  42. Breast. 2015 Nov;24 Suppl 2:S149-53 [PMID: 26299406]
  43. Nutr Cancer. 2022;74(4):1411-1419 [PMID: 34282978]
  44. J Sci Food Agric. 2013 Dec;93(15):3643-53 [PMID: 23765679]
  45. Pharmaceuticals (Basel). 2022 Jun 25;15(7): [PMID: 35890092]
  46. J Food Biochem. 2020 May;44(5):e13181 [PMID: 32173879]
  47. Future Sci OA. 2016 Jul 15;2(3):FSO135 [PMID: 28031979]
  48. Pharmaceutics. 2022 Dec 01;14(12): [PMID: 36559176]
  49. Cancer Treat Rev. 2008 Jun;34(4):378-90 [PMID: 18367336]
  50. J Med Food. 2004 Summer;7(2):117-21 [PMID: 15298755]
  51. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  52. J Antimicrob Chemother. 2004 Nov;54(5):909-14 [PMID: 15456732]
  53. Cancer Lett. 2004 Nov 8;215(1):53-9 [PMID: 15374632]
  54. Biomolecules. 2020 Jan 30;10(2): [PMID: 32019140]
  55. Eur J Pharm Biopharm. 2015 Jun;93:52-79 [PMID: 25813885]
  56. Front Chem. 2022 Jun 22;10:904973 [PMID: 35815210]
  57. Front Pharmacol. 2017 May 16;8:261 [PMID: 28559844]
  58. Nat Commun. 2018 Apr 12;9(1):1410 [PMID: 29650952]
  59. Methods Mol Biol. 2014;1141:77-101 [PMID: 24567132]
  60. Annu Rev Entomol. 2012;57:405-24 [PMID: 21942843]
  61. Discov Nano. 2024 Feb 14;19(1):27 [PMID: 38353827]
  62. Front Oncol. 2022 Jul 14;12:930125 [PMID: 35912195]
  63. Cancers (Basel). 2019 Nov 25;11(12): [PMID: 31769416]
  64. Food Chem Toxicol. 2011 Feb;49(2):533-6 [PMID: 21093522]
  65. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 May;35(3):337-9 [PMID: 15181829]
  66. Int J Cancer. 2005 Oct 20;117(1):1-7 [PMID: 15880398]
  67. 3 Biotech. 2022 Feb;12(2):49 [PMID: 35127304]
  68. Chem Rev. 2019 Apr 24;119(8):4819-4880 [PMID: 30920815]
  69. Saudi Pharm J. 2021 Sep;29(9):999-1012 [PMID: 34588846]
  70. J Am Chem Soc. 2016 Sep 7;138(35):11128-31 [PMID: 27532322]
  71. Foods. 2021 Oct 14;10(10): [PMID: 34681488]
  72. BMC Complement Med Ther. 2023 Jan 9;23(1):6 [PMID: 36624422]
  73. Front Pharmacol. 2018 Nov 02;9:1260 [PMID: 30450050]
  74. ScientificWorldJournal. 2019 Apr 1;2019:3659432 [PMID: 31057339]
  75. Pharmaceutics. 2022 Aug 26;14(9): [PMID: 36145548]
  76. Pharmazie. 2022 Jun 1;77(6):172-178 [PMID: 35751165]
  77. Cancer Lett. 2005 Jul 8;225(1):41-52 [PMID: 15922856]
  78. Med Sci Monit. 2019 Sep 04;25:6631-6638 [PMID: 31482864]
  79. J Agric Food Chem. 2003 Nov 5;51(23):6696-701 [PMID: 14582962]
  80. Front Chem. 2022 Jun 14;10:927595 [PMID: 35774863]
  81. Cancers (Basel). 2021 Jul 06;13(14): [PMID: 34298604]
  82. ACS Appl Mater Interfaces. 2021 Jun 16;: [PMID: 34130450]
  83. Nutr Cancer. 2022;74(6):2196-2206 [PMID: 34607477]
  84. ACS Omega. 2024 Mar 04;9(11):12622-12634 [PMID: 38524461]
  85. Int J Cancer. 2002 Jan 1;97(1):72-81 [PMID: 11774246]
  86. Int J Mol Sci. 2020 May 02;21(9): [PMID: 32370233]
  87. Phytomedicine. 2005 Apr;12(4):299-304 [PMID: 15898708]
  88. J Clin Pathol. 1993 Feb;46(2):189-90 [PMID: 8459046]
  89. Anticancer Res. 1999 Nov-Dec;19(6B):5435-43 [PMID: 10697574]
  90. Nanoscale Adv. 2022 Nov 3;4(24):5233-5244 [PMID: 36540116]
  91. Pharmaceutics. 2022 Sep 06;14(9): [PMID: 36145632]
  92. Pharmaceutics. 2022 Jun 24;14(7): [PMID: 35890232]
  93. Oncol Rep. 2017 Aug;38(2):611-624 [PMID: 28627697]
  94. Food Chem Toxicol. 2006 May;44(5):616-25 [PMID: 16243420]
  95. Toxicol Lett. 2005 May 16;157(1):49-56 [PMID: 15795093]
  96. Sci Rep. 2017 Jun 19;7(1):3782 [PMID: 28630399]
  97. J Chromatogr A. 2010 Nov 19;1217(47):7345-50 [PMID: 20961551]
  98. Oncol Rep. 2002 Jul-Aug;9(4):757-60 [PMID: 12066204]
  99. Science. 2006 Feb 10;311(5762):808-11 [PMID: 16469917]
  100. Biosci Rep. 2018 Dec 11;38(6): [PMID: 30473536]
  101. Gels. 2023 Mar 09;9(3): [PMID: 36975657]
  102. Nutr Cancer. 2003;45(2):195-202 [PMID: 12881014]
  103. Food Chem Toxicol. 2009 Oct;47(10):2479-83 [PMID: 19595732]
  104. Sci Data. 2018 Aug 28;5:180172 [PMID: 30152811]
  105. Acta Pharm Sin B. 2014 Apr;4(2):120-7 [PMID: 26579373]
  106. Methods Mol Biol. 2014;1141:165-84 [PMID: 24567139]
  107. ACS Omega. 2022 Dec 19;8(1):1017-1025 [PMID: 36643489]
  108. IET Nanobiotechnol. 2021 Oct;15(8):654-663 [PMID: 34694719]
  109. Pharmaceutics. 2023 Jul 29;15(8): [PMID: 37631258]
  110. Adv Drug Deliv Rev. 2016 Mar 1;98:3-18 [PMID: 26546465]
  111. Pharmaceuticals (Basel). 2020 Oct 29;13(11): [PMID: 33138099]
  112. Chem Biodivers. 2022 Oct;19(10):e202200397 [PMID: 36097678]
  113. Int J Biol Macromol. 2020 Dec 1;164:3645-3655 [PMID: 32795576]
  114. Antioxidants (Basel). 2022 Apr 25;11(5): [PMID: 35624695]
  115. CA Cancer J Clin. 2017 Mar;67(2):93-99 [PMID: 28094848]
  116. J Food Sci. 2014 Jul;79(7):R1231-49 [PMID: 24888440]
  117. Signal Transduct Target Ther. 2024 Feb 21;9(1):34 [PMID: 38378653]
  118. Front Pharmacol. 2013 Mar 14;4:28 [PMID: 23504227]
  119. Drug Deliv. 2022 Dec;29(1):2190-2205 [PMID: 35815706]
  120. Molecules. 2020 Aug 15;25(16): [PMID: 32824172]
  121. Nutr Cancer. 2006;55(1):86-93 [PMID: 16965245]
  122. Front Pharmacol. 2021 Feb 03;12:601626 [PMID: 33613290]
  123. J Nutr Biochem. 2008 Jun;19(6):347-61 [PMID: 18499033]
  124. Food Chem Toxicol. 2008 Feb;46(2):446-75 [PMID: 17996351]
  125. Nano Lett. 2020 Aug 12;20(8):6191-6198 [PMID: 32697585]
  126. Nutr Cancer. 2009;61(5):640-8 [PMID: 19838938]
  127. Heliyon. 2023 Feb 14;9(2):e13684 [PMID: 36865478]
  128. Molecules. 2021 Dec 06;26(23): [PMID: 34885992]
  129. Expert Opin Pharmacother. 2005 Jun;6(7):1073-94 [PMID: 15957963]
  130. Int J Biol Macromol. 2022 Jun 15;210:742-751 [PMID: 35513100]
  131. Front Bioeng Biotechnol. 2021 Jul 22;9:703684 [PMID: 34368098]
  132. Pharm Dev Technol. 2022 Jan;27(1):63-71 [PMID: 34939892]
  133. Int J Nanomedicine. 2020 Oct 08;15:7651-7666 [PMID: 33116493]
  134. BMC Pharmacol Toxicol. 2021 Sep 30;22(1):52 [PMID: 34587996]
  135. In Vivo. 2003 Nov-Dec;17(6):553-9 [PMID: 14758720]
  136. Eur J Dermatol. 2010 Nov-Dec;20(6):685-92 [PMID: 20840911]
  137. Int J Pharm. 2022 Mar 25;616:121558 [PMID: 35143904]
  138. Int J Food Microbiol. 2004 Aug 1;94(3):223-53 [PMID: 15246235]
  139. Front Pharmacol. 2022 Sep 05;13:946161 [PMID: 36133807]
  140. Breast Cancer Res Treat. 2009 Nov;118(1):131-7 [PMID: 19189211]
  141. Int J Mol Sci. 2021 Apr 13;22(8): [PMID: 33924640]
  142. Acc Chem Res. 2020 Dec 15;53(12):2936-2949 [PMID: 33275845]
  143. Front Immunol. 2022 May 30;13:882718 [PMID: 35707536]

Word Cloud

Created with Highcharts 10.0.0EOstargetingnanocarrierstherapeuticcancerstrategiestreatmentdiverseanticancerpotentialchallengesnanoparticlesreviewincludingCancercomplexglobalhealthburdennecessitatesdevelopmentinnovativechemotherapyremainsprimaryapproachseveresideeffectschemoresistancedrivesearchnovelalternativesEssentialoilsconsistingbioactivephytochemicalsofferpromiseagentsHoweverlimitationsinstabilitylimitedbioavailabilitynon-specifichindercircumventedutilizingnanosystemsefficientdeliveryplatformshighlightsaccumulatingevidencebasedloadingseveralpolymericnanoemulsionsnanofiberslipid-basednanocapsulesnanostructuresniosomesliposomeseffectiveregimenscoversextractionchemicalcompositionmechanismsactionvarioustumorsAdditionallydelveslandscapeadvantagesconsiderationsEOencapsulationeffectivenessEO-loadedexaminedhighlightingenhancedcellularuptakecontrolleddrugreleaseimprovedefficacyFinallyaddressesexistingfutureperspectivesemphasizingclinicaltranslationpersonalizedmedicineapproachesBeyondaromatherapy:canessentialoilloadedrevolutionizetreatment?

Similar Articles

Cited By

No available data.